PapersFlow Research Brief
Gestational Trophoblastic Disease Studies
Research Guide
What is Gestational Trophoblastic Disease Studies?
Gestational Trophoblastic Disease Studies is a field of medical research focused on the diagnosis, management, genetic analysis, epidemiology, pathology, clinical presentation, treatment outcomes, and molecular genetics of gestational trophoblastic diseases, including hydatidiform mole, choriocarcinoma, and placental site trophoblastic tumor.
The field encompasses 54,488 published works on conditions such as molar pregnancy and trophoblastic tumors. Research addresses prenatal diagnosis, chemotherapy, immunohistochemistry, and genetic and epigenetic analysis. Key studies detail epidemiology, pathology, and management of hydatidiform mole.
Topic Hierarchy
Research Sub-Topics
Hydatidiform Mole Management
This sub-topic covers diagnosis, histopathological classification, and surveillance protocols for complete and partial hydatidiform moles. Researchers evaluate risk factors for persistent gestational trophoblastic neoplasia post-evacuation.
Choriocarcinoma Chemotherapy
This sub-topic examines multi-agent chemotherapy regimens (EMA-CO, EP/EMA) for choriocarcinoma and high-risk disease. Studies report long-term survival rates, toxicity profiles, and salvage therapy for resistant cases.
Gestational Trophoblastic Neoplasia Epidemiology
This sub-topic analyzes incidence patterns, geographic variations, risk factors (age, prior mole, ethnicity), and global registries of gestational trophoblastic neoplasia. Researchers identify etiologic factors and prevention strategies.
Molecular Genetics Hydatidiform Moles
This sub-topic investigates genomic imprinting defects, paternal uniparental disomy, and NLRP7/ KHDC3L mutations causing recurrent hydatidiform moles. Researchers develop genetic diagnostic panels for familial cases.
Placental Site Trophoblastic Tumor
This sub-topic studies the clinical behavior, immunohistochemical markers (human placental lactogen), and surgical/chemotherapy management of PSTT. Researchers address prognostic factors and fertility-sparing approaches.
Why It Matters
Gestational Trophoblastic Disease Studies guide clinical management of rare pregnancy-related tumors, enabling effective diagnosis and treatment to preserve fertility and achieve high cure rates. Lurain (2010) outlined epidemiology, pathology, clinical presentation, diagnosis, and hydatidiform mole management, supporting suction curettage as standard therapy with hCG monitoring to detect persistent disease. Seckl et al. (2010) detailed comprehensive approaches for choriocarcinoma and placental site trophoblastic tumor, emphasizing chemotherapy regimens that yield survival rates over 90% for low-risk cases and multi-agent protocols for high-risk cases. Vaitukaitis et al. (1972) developed a radioimmunoassay for specific hCG measurement despite LH interference, revolutionizing prenatal diagnosis and post-treatment surveillance. These advances reduce maternal mortality and inform global health strategies for reproductive disorders.
Reading Guide
Where to Start
"Gestational trophoblastic disease" by Seckl et al. (2010), as it provides a broad, accessible overview of pathology, diagnosis, and management across the disease spectrum, ideal for building foundational knowledge.
Key Papers Explained
Seckl et al. (2010) in "Gestational trophoblastic disease" synthesizes epidemiology, diagnosis, and therapy, building on Lurain (2010) in "Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole," which details mole-specific pathology and initial management. Vaitukaitis et al. (1972) in "A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone" underpins hCG-based diagnostics central to both papers. Benedet (2000) "Editorial" contextualizes clinical guidelines evolution.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research emphasizes genetic analysis of molar pregnancies and chemotherapy optimization for rare variants like placental site trophoblastic tumor, as foundational works by Seckl et al. (2010) and Lurain (2010) highlight needs for molecular diagnostics and risk-stratified therapies.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Everolimus for Advanced Pancreatic Neuroendocrine Tumors | 2011 | New England Journal of... | 2.8K | ✓ |
| 2 | Cannabis use in adolescence and risk for adult psychosis: long... | 2002 | BMJ | 1.4K | ✓ |
| 3 | Editorial | 2000 | International Journal ... | 1.1K | ✕ |
| 4 | Everolimus plus octreotide long-acting repeatable for the trea... | 2011 | The Lancet | 1.0K | ✕ |
| 5 | Gestational trophoblastic disease | 2010 | The Lancet | 966 | ✕ |
| 6 | A radioimmunoassay which specifically measures human chorionic... | 1972 | American Journal of Ob... | 887 | ✕ |
| 7 | Functioning Insulinoma—Incidence, Recurrence, and Long-Term Su... | 1991 | Mayo Clinic Proceedings | 879 | ✕ |
| 8 | Gestational trophoblastic disease I: epidemiology, pathology, ... | 2010 | American Journal of Ob... | 778 | ✕ |
| 9 | Primary intracranial germ cell tumors: a clinical analysis of ... | 1997 | Journal of neurosurgery | 767 | ✕ |
| 10 | Sites of ectopic pregnancy: a 10 year population-based study o... | 2002 | Human Reproduction | 760 | ✕ |
Frequently Asked Questions
What is gestational trophoblastic disease?
Gestational trophoblastic disease includes hydatidiform mole, choriocarcinoma, and placental site trophoblastic tumor, abnormal placental proliferations arising from pregnancy. Seckl et al. (2010) describe its spectrum from benign moles to malignant tumors requiring chemotherapy. Diagnosis relies on elevated hCG, ultrasound, and histopathology.
How is hydatidiform mole managed?
Hydatidiform mole management involves suction evacuation followed by serial hCG monitoring to detect persistent disease. Lurain (2010) specifies this approach for complete and partial moles, with hysterectomy considered for older patients or uncontrolled bleeding. Post-evacuation contraception prevents new pregnancies that could confound hCG surveillance.
What role does hCG play in diagnosis?
Human chorionic gonadotropin (hCG) serves as the primary biomarker for gestational trophoblastic disease due to abnormal trophoblast proliferation. Vaitukaitis et al. (1972) introduced a radioimmunoassay that specifically measures hCG in the presence of luteinizing hormone. Persistently elevated hCG post-evacuation indicates malignant transformation requiring chemotherapy.
What are the treatment outcomes for choriocarcinoma?
Choriocarcinoma responds well to chemotherapy, with survival exceeding 90% for low-risk metastatic disease using methotrexate or actinomycin D. Seckl et al. (2010) report multi-agent regimens like EMA/CO achieving cure rates over 80% in high-risk cases. Early diagnosis via hCG monitoring improves prognosis.
How is gestational trophoblastic disease diagnosed?
Diagnosis combines clinical presentation like vaginal bleeding and hyperemesis, ultrasound showing characteristic 'snowstorm' appearance, and markedly elevated hCG. Lurain (2010) emphasizes histopathological confirmation after evacuation. Genetic analysis distinguishes complete from partial moles.
Open Research Questions
- ? What genetic and epigenetic markers best predict progression from hydatidiform mole to persistent gestational trophoblastic neoplasia?
- ? How can non-invasive prenatal diagnostics improve early detection of molar pregnancies?
- ? Which chemotherapy regimens optimize outcomes for placental site trophoblastic tumors resistant to standard treatments?
- ? What epidemiological factors drive regional variations in gestational trophoblastic disease incidence?
- ? How does maternal age influence the molecular pathogenesis of complete versus partial hydatidiform moles?
Recent Trends
The field maintains 54,488 works with steady contributions on genetic and epigenetic analysis, chemotherapy, and immunohistochemistry, as evidenced by core papers like Seckl et al. and Lurain (2010).
2010No recent preprints or news in the last 12 months indicate stable focus on established management protocols.
Research Gestational Trophoblastic Disease Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Gestational Trophoblastic Disease Studies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers